Masaaki Kawano
Saitama Medical University.Japan
Title: Medical application of a nanocapsule derived from a viral capsid protein
Biography
Biography: Masaaki Kawano
Abstract
Development of protein-based delivery-carriers for diagnosis and therapy has progressed by using viral capsid protein. Simian virus 40 (SV40) is a small non-enveloped DNA virus of polyomaviridae. The capsid structure of SV40 is 45 nm in diameter and is formed by 72 copies of pentamers composed of five VP1 major capsid proteins (360 molecules in total). When expressed in insect cells using recombinant baculovirus, VP1 is self-assembled into virus-like particles (VLPs) of 45 nm in diameter as the naturally assembled SV40 virus capsid. VLPs isolated from the cells are disassembled in vitro into VP1-pentamers by the addition of DTT and EGTA. These VP1-pentamers are self-reassembled in vitro into VLPs under appropriate conditions. In this reassembly, VLPs can encapsulate various materials such as DNA and proteins. It is also possible to modify VP1 for providing VLPs with the ability of targeting of specific cell. It was recently indicated that SV40 VLPs could be a promising vaccine platform. Thus, VP1 has a great potential for developing a variety of nanocapsule for medical application. In this presentation, we summarize our technology using SV40 VP1 for medical application and show an application of SV40 VP1 as an efficient vaccine nanocapsule. Indeed, vaccination of SV40 VP1 nanocapsule inserted HLA-A2 restricted cytotoxic T lymphocyte (CTL) epitope of GILGFVFTL of influenza virus matrix protein 1 (M1) efficiently induced CTLs against M1 with fifty times more than classical incomplete freund’s adjuvant method.
